Compare ACMR & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACMR | DYN |
|---|---|---|
| Founded | 1998 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | 2017 | 2020 |
| Metric | ACMR | DYN |
|---|---|---|
| Price | $38.90 | $19.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 16 |
| Target Price | ★ $43.00 | $40.25 |
| AVG Volume (30 Days) | 1.1M | ★ 3.4M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.16 | N/A |
| EPS | ★ 1.72 | N/A |
| Revenue | ★ $880,350,000.00 | N/A |
| Revenue This Year | $18.22 | N/A |
| Revenue Next Year | $16.80 | N/A |
| P/E Ratio | $22.53 | ★ N/A |
| Revenue Growth | ★ 20.77 | N/A |
| 52 Week Low | $14.65 | $6.36 |
| 52 Week High | $45.12 | $27.59 |
| Indicator | ACMR | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 63.86 | 47.95 |
| Support Level | $32.20 | $19.20 |
| Resistance Level | $37.85 | $20.80 |
| Average True Range (ATR) | 1.86 | 1.49 |
| MACD | 0.96 | -0.29 |
| Stochastic Oscillator | 78.25 | 20.70 |
ACM Research Inc supplies advanced, innovative capital equipment developed for the world-wide semiconductor industry. Fabricators of advanced integrated circuits, or chips, can use its wet-cleaning and other front-end processing tools in numerous steps to improve product yield, even at increasingly advanced process nodes. It has designed these tools for use in fabricating foundry, logic and memory chips, including dynamic random-access memory, or DRAM, and 3D NAND-flash memory chips. The company also develops, manufactures and sells advanced packaging tools to wafer assembly and packaging customers.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.